These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate]. Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044 [TBL] [Abstract][Full Text] [Related]
4. Histopathological effects of androgen deprivation in prostatic cancer. Civantos F; Soloway MS; Pinto JE Semin Urol Oncol; 1996 May; 14(2 Suppl 2):22-31. PubMed ID: 8725888 [TBL] [Abstract][Full Text] [Related]
5. [The role of neoadjuvant treatment prior to radical prostatectomy]. Sassine AM; Schulman C Acta Urol Belg; 1992; 60(3):61-71. PubMed ID: 1492635 [TBL] [Abstract][Full Text] [Related]
6. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Fair WR; Betancourt JE Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380 [TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
8. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Van der Kwast TH; Têtu B; Fradet Y; Dupont A; Gomez J; Cusan L; Diamond P; Labrie F Prostate; 1996 Apr; 28(4):227-31. PubMed ID: 8602398 [TBL] [Abstract][Full Text] [Related]
10. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426 [TBL] [Abstract][Full Text] [Related]
11. Total cystoprostatectomy in the treatment of locally advanced prostate carcinoma. Sato K; Tsuchiya N; Habuchi T; Satoh S; Shimoda N; Kato T Aktuelle Urol; 2003 Jul; 34(4):259-61. PubMed ID: 14566679 [TBL] [Abstract][Full Text] [Related]
12. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301 [TBL] [Abstract][Full Text] [Related]
14. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Amling CL; Blute ML; Bergstralh EJ; Slezak JM; Martin SK; Zincke H Semin Urol Oncol; 1997 Nov; 15(4):222-9. PubMed ID: 9421449 [TBL] [Abstract][Full Text] [Related]
15. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up after triple treatment of prostate cancer stage pT3. Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383 [TBL] [Abstract][Full Text] [Related]
17. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer. Noguchi M; Noda S; Nakashima O; Kojiro M Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076 [TBL] [Abstract][Full Text] [Related]
18. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340 [TBL] [Abstract][Full Text] [Related]
19. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S; J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055 [TBL] [Abstract][Full Text] [Related]
20. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]